Claudia Pena-Rossi

Title: Claudia Pena-Rossi: Innovator in OX40R Binding Agents

Introduction

Claudia Pena-Rossi is a prominent inventor based in Geneva, Switzerland. She has made significant contributions to the field of biomedical research, particularly in the development of OX40R binding agents. With a total of 2 patents, her work focuses on innovative solutions for diseases related to activated T cells.

Latest Patents

Claudia's latest patents include the invention of peptides isolated from the extracellular domain of OX40 Ligand (OX40L). These peptides are capable of binding to the OX40 Receptor (OX40R) and inhibiting the OX40R-OX40L interaction. Such peptides, along with fusion proteins that comprise them, can be utilized as OX40R binding agents. They compete with natural OX40L to block OX40R-mediated cell signaling, which is crucial in the prophylaxis and treatment of various diseases associated with activated T cells.

Career Highlights

Claudia Pena-Rossi is currently employed at Merck Serono S.A., where she continues to advance her research in the field of immunology. Her work has garnered attention for its potential applications in therapeutic interventions.

Collaborations

Claudia collaborates with her coworker, Claudio Soto-Jara, to further enhance the research and development of their innovative projects.

Conclusion

Claudia Pena-Rossi's contributions to the field of biomedical research, particularly through her patents on OX40R binding agents, highlight her role as a leading inventor. Her work promises to impact the treatment of diseases related to activated T cells significantly.